GlassScriptPhysician profile
Cameron R Barnes
NPI 1437113982
$4,117.12
in general payments reported to CMS, 2019-2025
32 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $300 · 2021: $580 · 2022: $926 · 2023: $691 · 2024: $436 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $799.89 | 2019-2025 | Erleada |
| Blue Earth Diagnostics | $606.26 | 2021-2025 | Posluma |
| Abbvie INC. | $454.84 | 2021-2025 | Botox, Lupron Depot |
| Boston Scientific Corporation | $429.21 | 2019-2024 | Rezum Generator, Greenlight Xps |
| Pfizer INC. | $326.72 | 2019-2025 | |
| Medtronic USA, INC. | $231.18 | 2019-2020 | |
| Procept Biorobotics Corporation | $172.92 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Axonics, INC. | $168.43 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $113.26 | 2019-2024 | Provenge |
| Olympus America INC. | $97.04 | 2022 | |
| Sumitomo Pharma America, INC. | $93.35 | 2023-2024 | Orgovyx |
| Amgen INC. | $91.51 | 2021-2023 | Prolia |
| Astellas Pharma US INC | $73.27 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $58.99 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $45.31 | 2020-2025 | Bridion |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $44.50 | 2024-2025 | Adstiladrin |
| Ambu INC. | $35.59 | 2022-2023 | |
| Accord Healthcare, INC. | $35.20 | 2022-2025 | |
| Urogen Pharma, INC. | $33.53 | 2023 | Jelmyto |
| Rochester Medical Corporation | $28.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.92 | 2023 | Lynparza |
| Verity Pharmaceuticals INC. | $19.45 | 2023 | Trelstar |
| Foundation Medicine, INC. | $19.07 | 2021 | |
| Genzyme Corporation | $17.70 | 2019 | |
| Photocure INC | $17.01 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.04 | 2019 | |
| Teleflex LLC | $13.87 | 2021 | |
| Neotract INC. | $13.59 | 2020 | |
| Clovis Oncology, INC. | $12.17 | 2020 | |
| Endo Pharmaceuticals INC. | $11.44 | 2019 | |
| Healthtronics Stone Solutions, LLC | $9.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.